EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Primary resistance to nivolumab plus ipilimumab therapy affects second‐line treatment outcomes in patients with metastatic renal cell carcinoma

Kanami Mori, Kazuyuki Numakura iD, Yuto Matsushita, Takahiro Kojima, Takahiro Osawa iD, Tomokazu Sazuka, Shingo Hatakeyama, Keisuke Goto, Kazutoshi Yamana, Shuya Kandori iD, Takahiro Kimura, Naotaka Nishiyama und 9 weitere

Cancer Science · 2025

DOI: 10.1111/cas.16326 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Science, 2025. Verfasst von Kanami Mori und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Akita University Graduate School of Medicine, Akita, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Nivolumab, Ipilimumab, Kidney Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Grant-in-Aid for Scientific Research, Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nivolumab plus ipilimumab (NIVO+IPI) has a long‐term response rate of 30% for patients with metastatic renal cell carcinoma (mRCC). However, 20% of patients develop primary resistant disease (PRD) to NIVO+IPI and show poor survival outcomes. In this study, we aimed to evaluate the effect of PRD as a second‐line treatment in patients with mRCC. The data used in this multi‐institutional, retrospective cohort were collected between August 2015 and January 2023. In total, 189 patients with mRCC were treated with NIVO+IPI and then with a vascular endothelial growth factor receptor‐tyrosine kinase inhibitor. Associations between PRD and progression‐free survival of second‐line treatment (PFS), progression‐free survival 2 (PFS2), and overall survival (OS) were analyzed. The median age at NIVO+IPI initiation was 67 years in the male‐dominant population ( n = 140, 74.1%), and most patients had clear cell histology ( n = 140, 74.1%). PRD was recorded in 42 (22.2%) of 189 patients during NIVO+IPI therapy. Patients who experienced PRD showed poor PFS (hazard ratio [HR], 1.788; 95% confidence interval [CI], 1.176–2.718; p = 0.007), PFS2 (HR, 4.127; 95% CI, 2.649–6.431; p < 0.001), and OS (HR, 3.330; 95% CI, 2.040–5.437; p < 0.001). Before starting second‐line therapy, patients with PRD tended to have a poor performance status compared with non‐PRD patients and a higher IMDC risk. Second‐line drug therapy was not associated with treatment outcomes in patients with PRD. PRD in patients with mRCC receiving NIVO+IPI as first‐line treatment was associated with poor clinical course, even with second‐line therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellNivolumabIpilimumabKidney NeoplasmsDrug Resistance, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleAgedMiddle AgedRetrospective StudiesProgression-Free SurvivalTreatment OutcomeAged, 80 and overAdult

Stichwörter der Autor:innen

metastatic renal cell carcinomanivolumab plus ipilimumabprimary resistancesecond‐line treatmentsurvival

Substanzen

NivolumabIpilimumab

Autor:innen und Institutionen

  • Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.
  • Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Department of Urology, Aichi Cancer Center, Nagoya, Japan.
  • Department of Renal and Genitourinary Surgery, Hokkaido University, Sapporo, Japan.
  • Department of Urology, Graduate School of Medicine and School of Medicine, Chiba University, Chiba, Japan.
  • Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

ORCID-Profile: Kazuyuki Numakura, Takahiro Osawa, Shuya Kandori

Förderung

  • Grant-in-Aid for Scientific Research, Japan

Zitieren

APA

Mori, K., Numakura, K., Matsushita, Y., Kojima, T., Osawa, T., Sazuka, T., Hatakeyama, S., Goto, K., Yamana, K., Kandori, S., Kimura, T., Nishiyama, N., Bando, Y., Fujita, K., Ueda, K., Tanaka, H., Tomida, R., Kurahashi, T., Kitamura, H., …, & Habuchi, T. (2025). Primary resistance to nivolumab plus ipilimumab therapy affects second‐line treatment outcomes in patients with metastatic renal cell carcinoma. Cancer Science. https://doi.org/10.1111/cas.16326

Vancouver

Mori K, Numakura K, Matsushita Y, Kojima T, Osawa T, Sazuka T, et al. Primary resistance to nivolumab plus ipilimumab therapy affects second‐line treatment outcomes in patients with metastatic renal cell carcinoma. Cancer Science. 2025. doi:10.1111/cas.16326

BibTeX
@article{Mori2025,
  author = {Mori, Kanami and Numakura, Kazuyuki and Matsushita, Yuto and Kojima, Takahiro and Osawa, Takahiro and Sazuka, Tomokazu and Hatakeyama, Shingo and Goto, Keisuke and Yamana, Kazutoshi and Kandori, Shuya and Kimura, Takahiro and Nishiyama, Naotaka and Bando, Yukari and Fujita, Kazutoshi and Ueda, Kosuke and Tanaka, Hajime and Tomida, Ryotaro and Kurahashi, Toshifumi and Kitamura, Hiroshi and Miyake, Hideaki and Habuchi, Tomonori},
  title = {Primary resistance to nivolumab plus ipilimumab therapy affects second‐line treatment outcomes in patients with metastatic renal cell carcinoma},
  journal = {Cancer Science},
  year = {2025},
  doi = {10.1111/cas.16326}
}
Kostenlos starten →